Robert A Brown1, Sridar Narayanan2, Nikola Stikov2, Stuart Cook2, Diego Cadavid2, Leo Wolansky2, Douglas L Arnold2. 1. From the McConnell Brain Imaging Centre (R.A.B., S.N., N.S., D.L.A.), Montreal Neurological Institute and Hospital, Canada; Rutgers-New Jersey Medical School (S.C., D.C.), Newark, NJ; and Case Western Reserve University (L.W.), Cleveland, OH. robert.brown@mcgill.ca. 2. From the McConnell Brain Imaging Centre (R.A.B., S.N., N.S., D.L.A.), Montreal Neurological Institute and Hospital, Canada; Rutgers-New Jersey Medical School (S.C., D.C.), Newark, NJ; and Case Western Reserve University (L.W.), Cleveland, OH.
Abstract
OBJECTIVE: To compare magnetization transfer changes in new brain MRI lesions identified during monthly imaging in patients with multiple sclerosis (MS) randomized to treatment with 250 μg subcutaneous interferon-β-1b (IFN-β-1b) every other day or daily 20 mg glatiramer acetate (GA) in a post hoc study using data from the Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI (BECOME) trial. METHODS: T1-weighted images acquired with and without fat saturation pulses in the BECOME study were evaluated and found to exhibit magnetization transfer ratio (MTR) effects, and were used to compute MTR images (FSMTR). Forty-three participants who had the required imaging and new lesions, from the 75 originally randomized into the BECOME study, were included in this post hoc analysis and evaluated longitudinally during treatment to determine FSMTRDrop, an experimental measure of the completeness of FSMTR recovery in new lesions. Two sets of new brain MRI lesions were defined, one based on the appearance of gadolinium contrast enhancement (Gd lesions) and the other based on FSMTR decreases (ΔFSMTR lesions). RESULTS:A total of 887 Gd lesions were identified in 43 participants (19 GA, 24 IFN-β-1b) and 321 ΔFSMTR lesions in 32 participants (16 GA, 16 IFN-β-1b). Participants randomized to GA exhibited greater average postlesion FSMTR recovery than did those randomized to IFN-β-1b in both Gd (p < 0.0001) and ΔFSMTR (p < 0.0001) lesions. CONCLUSIONS: New brain lesions that developed during treatment with GA exhibited evidence of greater FSMTR recovery than during treatment with IFN-β-1b. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that MTR recovery in patients with MS with new MRI brain lesions is greater with GA than with IFN-β-1b.
RCT Entities:
OBJECTIVE: To compare magnetization transfer changes in new brain MRI lesions identified during monthly imaging in patients with multiple sclerosis (MS) randomized to treatment with 250 μg subcutaneous interferon-β-1b (IFN-β-1b) every other day or daily 20 mg glatiramer acetate (GA) in a post hoc study using data from the Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI (BECOME) trial. METHODS: T1-weighted images acquired with and without fat saturation pulses in the BECOME study were evaluated and found to exhibit magnetization transfer ratio (MTR) effects, and were used to compute MTR images (FSMTR). Forty-three participants who had the required imaging and new lesions, from the 75 originally randomized into the BECOME study, were included in this post hoc analysis and evaluated longitudinally during treatment to determine FSMTRDrop, an experimental measure of the completeness of FSMTR recovery in new lesions. Two sets of new brain MRI lesions were defined, one based on the appearance of gadolinium contrast enhancement (Gd lesions) and the other based on FSMTR decreases (ΔFSMTR lesions). RESULTS: A total of 887 Gd lesions were identified in 43 participants (19 GA, 24 IFN-β-1b) and 321 ΔFSMTR lesions in 32 participants (16 GA, 16 IFN-β-1b). Participants randomized to GA exhibited greater average postlesion FSMTR recovery than did those randomized to IFN-β-1b in both Gd (p < 0.0001) and ΔFSMTR (p < 0.0001) lesions. CONCLUSIONS: New brain lesions that developed during treatment with GA exhibited evidence of greater FSMTR recovery than during treatment with IFN-β-1b. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that MTR recovery in patients with MS with new MRI brain lesions is greater with GA than with IFN-β-1b.
Authors: Loredana La Mantia; Carlo Di Pietrantonj; Marco Rovaris; Giulio Rigon; Serena Frau; Francesco Berardo; Anna Gandini; Anna Longobardi; Bianca Weinstock-Guttman; Alberto Vaona Journal: Cochrane Database Syst Rev Date: 2014-07-26
Authors: Ives Levesque; John G Sled; Sridar Narayanan; A Carlos Santos; Steven D Brass; Simon J Francis; Douglas L Arnold; G Bruce Pike Journal: J Magn Reson Imaging Date: 2005-02 Impact factor: 4.813
Authors: V Dousset; R I Grossman; K N Ramer; M D Schnall; L H Young; F Gonzalez-Scarano; E Lavi; J A Cohen Journal: Radiology Date: 1992-02 Impact factor: 11.105
Authors: Jiwon Oh; Daniel Ontaneda; Christina Azevedo; Eric C Klawiter; Martina Absinta; Douglas L Arnold; Rohit Bakshi; Peter A Calabresi; Ciprian Crainiceanu; Blake Dewey; Leorah Freeman; Susan Gauthier; Roland Henry; Mathilde Inglese; Shannon Kolind; David K B Li; Caterina Mainero; Ravi S Menon; Govind Nair; Sridar Narayanan; Flavia Nelson; Daniel Pelletier; Alexander Rauscher; William Rooney; Pascal Sati; Daniel Schwartz; Russell T Shinohara; Ian Tagge; Anthony Traboulsee; Yi Wang; Youngjin Yoo; Tarek Yousry; Yunyan Zhang; Nancy L Sicotte; Daniel S Reich Journal: Neurology Date: 2019-02-20 Impact factor: 9.910
Authors: Caryl J Schwartzbach; Richard A Grove; Robert Brown; Debra Tompson; Florian Then Bergh; Douglas L Arnold Journal: J Neurol Date: 2016-11-25 Impact factor: 4.849
Authors: Shannon Kolind; Shawna Abel; Carolyn Taylor; Roger Tam; Cornelia Laule; David K B Li; Hideki Garren; Laura Gaetano; Corrado Bernasconi; David Clayton; Irene Vavasour; Anthony Traboulsee Journal: Neuroimage Clin Date: 2022-07-19 Impact factor: 4.891